BrightGene Bio-Medical Technology Co., Ltd. reported earnings results for the nine months ended September 30, 2022. For the nine months, the company reported sales was CNY 772.32 million compared to CNY 748.44 million a year ago. Revenue was CNY 772.32 million compared to CNY 748.44 million a year ago.

Net income was CNY 197.62 million compared to CNY 176.87 million a year ago. Basic earnings per share from continuing operations was CNY 0.48 compared to CNY 0.43 a year ago. Diluted earnings per share from continuing operations was CNY 0.48 compared to CNY 0.43 a year ago.